Early cost-effectiveness of tumor infiltrating lymphocytes (TIL) for second line treatment in advanced melanoma : A model-based economic evaluation
2018
Background
An emerging immunotherapy is infusion of tumor infiltrating Lymphocytes (TIL), with objective response rates of around 50% versus 19% for ipilimumab. As an Advanced Therapeutic Medicinal Products (ATMP), TIL is highly personalized and complex therapy. It requests substantial upfront investments from the hospital in: expensive lab-equipment, staff expertise and training, as well as extremely tight hospital logistics. Therefore, an early health economic modelling study, as part of a Coverage with Evidence Development (CED) program, was performed.
Keywords:
- Cancer research
- Melanoma
- Ipilimumab
- Cost-effectiveness analysis
- Medicine
- Personalized medicine
- Surgical oncology
- Immunotherapy
- ATMP
- Tumor-infiltrating lymphocytes
- Internal medicine
- Oncology
- Economic evaluation
- Progressive disease
- Clinical trial
- cost effectiveness
- Expected value of perfect information
- Value of information
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
26
References
7
Citations
NaN
KQI